At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
Oral OKT3 +1 moredrug
Likely dose
Oral OKT3 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Oral Anti-CD3 for the Treatment of Active Ulcerative Colitis
In Brief
A Phase 2 clinical trial evaluating Oral OKT3 and Omeprazole for Ulcerative Colitis. Completed, enrolled 6 participants across 1 site.
Detailed Summary
This study will assess the safety and efficacy of orally delivered short-term OKT3 in participants with active ulcerative colitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2011
Enrollment StartApr 2011
Primary CompletionMay 2013
TodayJul 2026
First PostedFeb 1, 2011
Enrollment StartApr 7, 2011
Primary CompletionMay 2, 2013
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 15.4 years ago
Interventions
Oral OKT3drug
1 mg or 2 mg Oral OKT3 will be given orally to participants once daily for 30 days
Omeprazoledrug
20 mg Omeprazole will be given orally to participants once daily for 30 days